Ampreloxetine hydrochloride is under clinical development by Theravance Biopharma and currently in Phase III for Orthostatic Hypotension. According to GlobalData, Phase III drugs for Orthostatic Hypotension does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ampreloxetine hydrochloride LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ampreloxetine hydrochloride overview
Ampreloxetine HCL (TD-9855) is under development for the treatment of multiple system atrophy (MSA) patients suffering with neurogenic orthostatic hypotension (NOH). The drug candidate is administered orally as a tablet and is a new molecular entity. It acts by targeting serotonin and norepinephrine reuptake.
See Also:
It was under development for the treatment of attention deficit hyperactivity disorder (ADHD) and fibromyalgia.
Theravance Biopharma overview
Theravance Biopharma is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; neurogenic orthostatic hypotension (nOH); gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease and gastroparesis and concurrent bacteremia. Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future payments made to Innoviva, Inc from Glaxo Group Limited or one of its affiliates. The company has subsidiaries in the US, Ireland and the UK. Theravance Biopharma is headquartered in Grand Cayman, Cayman Islands, the UK.
For a complete picture of Ampreloxetine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
